$heff's $tation of $tocks & $olid DD

[buckiii2]

ARIA
today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113)
ARIAD Pharmaceuticals, Inc. (ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The new results include an analysis of safety and efficacy for patients treated at select doses of brigatinib and an evaluation of intracranial central nervous system (CNS) antitumor activity.

The updated results were presented at the 2015 European Lung Cancer Conference (ELCC) being held in Geneva, Switzerland.

Phase 2 Dose Sub-Analysis

The data presented at ELCC focused on the 98 patients treated at doses of 90 mg/day (n=18), 90 mg/day for 1 week followed by escalation to 180 mg/day (n=32), and 180 mg/day (n=48) in the Phase 2 portion of the trial. All patients receiving these doses were evaluated for safety, and patients with ALK+ NSCLC (n=65) were evaluated for efficacy. The presentation at ELCC is based on patient data as of January 19, 2015 with a median follow-up of 40 weeks (range, 0.1 – 150+ weeks).

“The updated data on select doses from the Phase 1/2 trial show robust anti-tumor activity of brigatinib in patients with crizotinib-resistant ALK+ NSCLC, with responses now approaching one year,” stated Rafael Rosell, M.D., Director, Cancer Biology & Precision Medicine Program Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital in Barcelona, Spain. “Importantly, by starting at the 90 mg dose, we have seen a reduction of early-onset pulmonary events observed at the higher starting doses.”

http://finance.yahoo.com/news/ariad-presents-updated-clinical-data-113500971.html